The World In A Grain Of Sand

Take a deep dive into Pure Cycle with Mack Healy and Blair Willette from the team at KdT Ventures.

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss BioAge, a longevity biotech with a pipeline of therapies for diseases of aging including cardiometabolic disease and neuroinflammation. Please note that this episode was re...

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Cain McClary and Phil Grayeski discuss CG Oncology, the first biotech IPO of 2024. We dive into: The various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncolog...

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Ketan Yerneni and Mack Healy discuss Verve Therapeutics, a gene editing biotech tackling one of the most common chronic diseases: cardiovascular disease. We dive into: Base editing, and its advantages over tradi...

KdT Ventures presents The World in a Grain of Sand, where we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. In this episode, Patrick Malone and Mack Healy discuss the biopharma software juggernaut, Schrödinger. We dive into: Schrödinger's biophysics-based drug discovery platform, and the distinction from machine learning approache...

KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This episode, Amylyx Pharmaceuticals, a neuro biotech founded in a dorm room by two scrappy Brown undergrads. We discuss: the mechanism of action of Amylyx’s lead disease-modifying asset, and competitive positioning relativ...

KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Codiak BioSciences.

KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Royalty Pharma.

KdT Ventures Partners, Mack Healy & Phil Grayeski take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Sana Biotechnology.

KdT Ventures Partners, Mack Healy & Cain McClary take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Editas.

KdT Ventures Partners, Mack Healy & Rima Chakrabarti take a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Century Therapeutics.

The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that has or is hoping to go public within the biology realm. This month, Taysha GTx

The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, Atai

The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, Recursion Pharmaceuticals. 

The KdT Ventures team takes a deep dive into a specific S-1 filing from a company that is hoping to go public within the biology realm. This month, AbCellera.